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Summary 
We have developed a PCR assay that can detect a sin- 
gle Epstein-Barr virus (EBV) genome in the presence 
of 108 uninfected cells. Using this assay, we demon- 
strate that EBV persists, in the peripheral blood of all 
seropositive individuals tested, in CD19 +, CD23-, and 
CD80 (B7)- B cells. We further show that the virus in 
these cells is latent, but readily reactivated to produce 
infectious immortalizing virus; therefore, these cells 
represent a true site of latent persistence. EBV was 
not significantly detected in monocytes or T cells. The 
frequency of infected cells in nine healthy donors var- 
ied from 23 to 625 per 107 B cells, but was relatively 
stable for each individual over the course of 2 years. 
We conclude that the EBV-infected cells in vivo are B 
cells with a nonactivated phenotype. This represents 
a novel form of latency in normal B cells. 
Introduction 
Epstein-Barr virus (EBV) is a human herpesvirus that per- 
sists, like other herpes viruses, for the lifetime of the host 
(Klein and Klein, 1985). In vitro, the virus infects mature 
resting B cells and causes them to become continuously 
proliferating lymphoblasts, a process called immortaliza- 
tion (Miller, 1990). The proliferative potential of EBV- 
infected cells and lifetime exposure through persistence 
are believed to be major predisposing factors in the devel- 
opment of EBV-associated neoplasia. 
The mechanism of in vitro immortalization has been in- 
tensively studied; however, little is known about the nature 
of persistence in vivo (Klein, 1989, 1994). After infection, 
normal, healthy individuals continue to shed the virus in 
the saliva, allowing transmission to others. It is believed 
that these virions are produced by persistently infected 
epithelium (Sixbey et al., 1983). The virus is also found 
in B lymphocytes, where it persists in the absence of viral 
replication (Yao et al., 1989), suggesting a latent form of 
infection. B cells may be the essential site of latency, since 
it is known that an intact hematopoietic system is required 
for the long-term persistence of the virus in vivo (Gratama 
et al., 1988). 
The first studies that identified infected cells in vivo ex- 
ploited the fact that immortalized EBV B cell lines can be 
grown from peripheral blood (Yao et al., 1985; Lewin et 
al., 1987; Lam et al., 1991). However, since this outgrowth 
occurs predominantly by an indirect route involving re- 
lease of virus and reinfection in culture (Rickinson et al., 
1985), this method only detects cells capable of releasing 
virus. It cannot detect EBV-infected cells that do not re- 
lease infectious virus and cannot grow directly in culture. 
More recently, polymerase chain reaction (PCR) has been 
used to identify and measure relative levels of EBV in bulk 
cell populations from the peripheral blood of various do- 
nors (Saito et al., 1989; Ambinder et al., 1990; Telenti et 
al., 1990; Wagner et al., 1992). These studies generally 
assume that the virus is restricted to the B cell population; 
however, this has not been formally demonstrated to be 
true. In fact, the issue is complicated by recent evidence 
that EBV can be detected in certain T cell lymphomas, 
raising the possibility that the tropism of the virus in vivo 
may be broader than previously thought (Jones et al., 
1988). A thorough survey of the absolute numbers and 
phenotype of infected cells in the peripheral blood has yet 
to be performed. 
The only model for latent EBV infection in normal cells 
is the immortalized B cell obtained by in vitro infection. 
These cells are phenotypically lymphoblastoid, express- 
ing high levels of characteristic activation molecules such 
as CD23 and B7 (now.clustered as CD80) (Schlossman 
et al., 1994). They also express nine EBV-encoded latent 
proteins, six in the nucleus (Epstein-Barr nuclear antigens 
[EBNAs] 1-6) and three in the membrane (LMP1, LMP2A, 
and LMP2B) (Kieff and Liebowitz, 1990). All of these pro- 
teins, except EBNA1, have been demonstrated to be tar- 
gets for cytotoxic T cells (CTLs) (Khanna et al., 1992). 
EBV-seropositive individuals maintain high frequencies of 
CTLs against the latent proteins, suggesting that immortal- 
ized EBV lymphoblasts are present at some stage during 
the infection. Indeed, it is thought that the CTLs play an 
important role in controlling immortalized B lymphoblasts 
in vivo throughout he lifetime of the host, because immu- 
nosuppression can lead to immunoblastic lymphomas that 
are phenotypically related to the immortalized B lympho- 
blasts (Thomas et al., 1990). 
If immortalized lymphoblastoid B cells are the primary 
site of latency in vivo, then they must persist despite the 
CTL response. A plausible stochastic model to account 
for this can be constructed, since the immortalized EBV 
lymphoblasts are rapidly dividing and it takes a finite time 
for a CTL to locate its target. If the frequency of infected 
cells was low enough, an equilibrium could be achieved 
in which the rate at which new cells were generated by 
cell division equaled the rate at which the cells were lo- 
cated and killed by CTLs. Thus, the virus could persist for 
the lifetime of the host in a few latently infected B 
lymphoblasts. 
As a first step toward constructing a model for EBV la- 
tency in vivo, it is essential to know whether the EBV- 
infected cells are lymphoblastoid or not. The current study 
was initiated to resolve this question. To do this, we devel- 
oped a highly sensitive DNA PCR technique that allowed 
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Figure 1. EBV-Infected Cells Reside in the E (Non-T Cell) Fraction 
of PBMCs, and the Genome Copy Number Is Consistent with a Latent, 
Not a Lytic, Infection 
(A) PCR products from the E (upper panel) and T cells (E ÷) (bottom 
two panels) of donor 5 were analyzed by Southern blot as described 
in Experimental Procedures. The n umber of cells per sample was 106. 
The fraction of positive samples was 14 of 15 for the E population 
and 1 of 40 for the E- population. Arrows indicate the expected 495 
bp product from the BamHI W repeat. Lanes marked with a plus indi- 
cate the positive control (nine IARC 304 cells or 104 Namalwa cells). 
Lanes marked with an asterisk contain unlabeled ~X174 DNA digested 
with Hinfl, used as a molecular weight marker. The lanes indicated 
by a vertical line contain the experimental samples. 
(B) Southern blot analysis of PCR products of Namalwa cells (one or 
two genomes per cell) and E- cells. Lane 1 is the PCR signal from 
104 Namalwa cells (-104 EBV genome quivalents). Lanes 3-10 are 
the signals from samples of 106 B JAB cell (EBV) containing an aver- 
age of one Namalwa cell, and lanes 11-18 contain E cells diluted to 
give an average of one EBV + cell per sample. The arrow indicates the 
495 bp expected size of the PCR product. 
us to measure precisely the absolute number of EBV- 
infected cells in vivo and then characterize the form of the 
infection and the phenotype of the infected cells. We show 
that EBV in peripheral blood is predominantly in latently 
infected CD23-CD80- B cells. Therefore, these cells are 
different from EBV lymphoblastoid cells and must repre- 
sent a novel form of viral latency in normal infected B ceils. 
Results 
EBV-lnfected Cells in the Peripheral Blood Are 
Predominantly CD19 ÷, CD23-, and CD80- 
For most of our experiments, we used human peripheral 
blood mononuclear cells (PBMCs) depleted of T lympho- 
cytes by rosetting with sheep red blood cells. Before pro- 
ceeding, we established that EBV did not reside in the T 
cell population (E÷). To do this, we performed PCR analysis 
on the E- (B cells, monocytes, null cells) and E ÷ cells from 
four separate donors. The results for one donor are shown 
in Figure 1A. For this experiment, only samples of 106 cells 
are shown. Of the 15 samples of E- cells, 14 were positive, 
whereas only 1 of the 40 T cell samples was positive (i.e., 
one positive cell in 4 x 10 ~ cells). Limiting dilution analysis 
on the E- cells from this individual revealed that the fre- 
quency of EBV-infected cells was 1 in 1.7 x 10 s (data not 
shown); therefore, essentially all of the EBV-infected cells 
are in the E- population. Similar results were obtained 
with all four donors tested (data not shown). The positive 
signals in the T cell population could be accounted for 
by <0.5% contaminating E- cells. Therefore, if there are 
infected T cells, they are present at frequencies so low 
as to be indistinguishable from background signals due 
to cellular contamination. 
Having demonstrated that the EBV-infected cells reside 
in the E- population, we proceeded to fractionate these 
cells, based on B cell surface markers, using Dynabeads 
coated with appropriate antibodies, and then we estimated 
the frequency of EBV-infected cells in each population. 
The markers we chose were CD19, CD23, and CD80. 
CD19 is a lineage-specific marker that is expressed on all 
B cells and that allowed us to estimate what fraction of 
the infected E- cells were B cells. CD23 and CD80 are 
expressed on activated B cells and are highly expressed 
on immortalized EBV B lymphoblasts, as demonstrated 
in Figure 2A. Use of these markers allowed us to assess 
what fraction of the EBV-infected cells are lymphoblastoid 
in phenotype. The results for all three markers are summa- 
rized in Table 1. 
In the first experiments, the E- cells were fractionated 
into CD19 ÷ and CD19- populations. Examples of the 
Southern blot analysis of the PCR products from donor 5 
are shown in Figure 3. For the CD19- population, only 1 
of 10 samples was positive when 106 cells per sample 
were tested (Figure 3, lower panel). By comparison, serial 
dilutions of CD19 ÷ cells were all positive down to 2 x 104 
cells per sample, where five of the seven samples were 
positive. Results for 2 x 105 and 2 x 104 CD19 ÷ cells per 
sample are shown in the top two panels of Figure 3. The 
estimated frequency of EBV-infected cells in the two popu- 
lations is given in Table 1 for two donors. Essentially all 
of the EBV-infected cells were found in the B cell (CD19 ÷) 
population for both donors. The positive signal in the 
CD19- population from donor 5 could be accounted for 
by <0.15% contaminating CD19 ÷ cells. Therefore, if there 
are infected CD19- E- cells, they are present at frequen- 
cies so low as to be indistinguishable from background 
signals due to cellular contamination. 
Next the E- population was fractionated based on CD23 
expression. The fractionated E= cells were analyzed by 
fluorescence-activated cell sorting (FACS) with antibodies 
to CD23 and the pan-B cell marker CD20 to confirm that 
the depletion was effective. Results of the FACS analysis 
from one experiment, performed on donor 7, are shown 
in Figure 2B, and the Southern blot analysis of the PCR 
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Figure 2. FACS Analysis of Various Lymphocyte Populations 
(A) CD23 and CD80 are highly expressed on immortalized latently 
infected EBV B lymphoblastoid cells. IB4 cells (EBV lymphoblastoid 
cell) were stained with either biotinylated anti-CD23, anti-CD80, or an 
appropriate isotype control, followed by streptavidin-phycoerythrin. 
Stained cells were analyzed by FACScan. 
(B) FACS analysis demonstrating the efficiency of depletion of CD23 ÷ 
cells from E- cells. The E cells of donor 7 were stained with anti-CD23, 
anti-CD20, or isotype control antibodies before (upper panels) or after 
(lower panels) depleting with magnetic Dynabeads coated with the 
anti-CD23 monoclonal antibody EBVCS#5. The populations were pre- 
gated on the lymphocyte population to increase the accuracy of the 
analysis. Note that the CD23 + population, denoted by the bar M1 in 
the top left-hand histogram of the upper panel, is absent from the 
depleted population as shown in the top left-hand histogram of the 
lower panel. By comparison, the CD23- B cells remain undepleted 
(compare the top right-hand histograms tained with anti-CD20). 
Table 1. EBV-Carrying Cells Are CD19-, CD23, and CD80- 
Frequency of EBV ÷ Cells per 107 Total Cells 
Marker Donor Unfractionated Depleted Selected 
CD19" 5 Not determined 1 b 625 
9 Not determined <3 40 
CD23 ~ 7 83 166 <2 
9 48 t 18 <1 
CD80 ~ 5 43 31 <8 
a The CD19-- cells were 96% depleted for donor 5 and >99% depleted 
for donor 9 as judged by FACS analysis. 
b This is not a true frequency since it was based on one positive signal 
in 107 cells; see Figure 3. 
° The CD23 + ceils were >99% depleted for both donors. The FACS 
anaysis for donor 7 is shown in Figure 2B. 
The CD80 ÷ cells were 98% depleted. The FACS analysis is shown 
in Figure 2C. 
products from these cell populations are shown in Figure 
4. Figure 2B demonstrates that essentially all (>99%) of 
the CD23 ÷ B cells were selectively depleted, leaving be- 
hind the CD23- B cells. By comparison, the PCR analysis 
reveals that we were unable to deplete the EBV-infected 
cells significantly with anti-CD23. The same result was 
obtained when this experiment was repeated on a second 
donor (9). A summary of all of the results, presented in 
Table 1, indicates that EBV-carrying cells are 2- to 4-fold 
enriched in the CD23- population when compared with 
the unseparated fraction. 
We wished to confirm the CD23 result using CD80, a 
second independent marker for activated B cells and EBV 
lymphoblastoid cells. CD80 is only expressed on a small 
fraction of B cells in the peripheral blood (Freedman et 
al., 1987). To detect these cells efficiently, we stained the 
samples for both CD80 and the pan-B cell marker CD20 
and monitored the double-stained population. As shown 
in Figure 2C, a double-stained (CD20÷CD80 ÷) and a single- 
stained (CD20÷CD80 -) population of B cells is present (top 
left panel). Depletion with the antibody-coated beads was 
both efficient and specific since 98% of the CD80 ÷ B cells 
were removed, but the CD80- B cells were unaffected (Fig- 
ure 2C, top right panel). The results of the PCR analysis 
are summarized in Table 1. Again it was possible to dem- 
onstrate that, despite efficient depletion of the CD80 ÷ cells, 
most of the EBV-infected cells remained behind, indicating 
that they were CD80-. 
(C) FACS analysis demonstrating the efficiency of depletion of CD80 ÷ 
cells from E- cells. Two-dimensional contour plot FACS analysis of 
E cells from donor 5 unfractionated (left panels) and depleted (right 
panels) with magnetic Dynabeads coated with an anti-CD80 mono- 
clonal antibody. The cells were stained with biotinylated anti-CD80, 
FITC-conjugated CD20, or appropriate isotype controls. Because 
CD80 is present on such a small percentage of cells in peripheral 
blood, it was necessary to gate on the large CD20 ÷ cells to maximize 
the accuracy of the analysis. Note that the CD20*CD80 + cells in the 
unfractionated population (upper right-hand quadrant of the top left 
contour map) are significantly reduced from the depleted population 
(upper right-hand quadrant of the top right contour map) while the 
CD80 B cells (lower right-hand quadrant) remain undepleted. 
Cell 
596 
Cells: B (CD19+) 
#/Sample: 2.10 s 
#Positive: 7 /7  
I I I 
CD23+ 
#/Sample: 2.10 s 
#Positive: 0 /10  
I I I $ "k  -P 
Cells: B (CD19+) 
#/Sample: 2.10 4 
#Positive: 5 /7  
I I I 
,,-- Q .... Om 
- - X + 
Cells: M (E-,CD19-) 
#/Sample: 10 s 
#Positive: 1 /10  
I I I L L I 
Figure 3. EBV-Infected Cells Reside in the B Cell Fraction 
PCR products from the E- cells of donor 5 fractionated into CD19 + (B 
cells; upper two panels) and CD19 (predominantly monocytes; bottom 
panel) populations. For details ee the legend to Figure 1. The lanes 
indicated by minus contain egative controls (either no DNA or DNA 
from 106 BJAB cells). In the bottom panel, the fifth sample is the single 
positive. It and the first CD19 ÷ sample (top panel) probably did not 
transfer properly, resulting in distorted bands. 
For all these experiments, we have routinely analyzed 
the cell populations for both the percentage of B cells and 
the frequency of EBV-infected cells. Since we have shown 
that essentially all of the infected cells reside in the B cell 
compartment, we can use this information to calculate the 
frequency of EBV-infected B cells in the various B cell 
fractions. The results are presented in Table 2 in the col- 
umn labeled Observed. Furthermore, we also measured 
the percentage of CD23 +j- and CD80 +j- B cells. Since we 
know the frequency of EBV-infected cells in the unfraction- 
ated population, we can use this information to predict 
the expected frequency of EBV-infected cells in a given 
population, assuming all of the infected cells are of that 
phenotype. These results are also presented in Table 2 
in the column labeled Expected. Comparisons of the ob- 
served and the expected frequencies strikingly demon- 
strate that essentially all of the EBV-infected cells in the 
peripheral blood lack markers of the in vitro immortalized 
lymphoblasts. 
The Frequency of EBV-lnfected B Cells in Normal 
Adults and Its Stability over Time 
Having established that EBV resides predominantly inthe 
B cell compartment, we examined nine healthy seroposi- 
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Figure 4. EBV-lnfected Cells Reside in the CD23- B Cell Fraction 
Southern blot analysis of the PCR products from the CD23 + (upper 
panel) and CD23 (lower panels) populations from donor 7. For details 
see the legend to Figure 1. 
tive donors to gain insight into the range of absolute num- 
bers of infected cells in the normal population. PCR analy- 
sis was performed on E- cells, and the frequency in B 
cells was calculated based on the percentage of B cells 
as measured by FACS analysis for the pan-B cell marker 
CD20. Every donor had detectable levels of EBV-infected 
cells, and the frequencies ranged from 23 to 625 infected 
cells for every 10 T B cells, with a mean of 125. 
The set of measurements we initially obtained repre- 
sented single points in time for each individual. We wished 
to know whether these values represented the range pres- 
ent in the population or the fluctuation that could occur 
within a single individual. Two donors, one with a high 
frequency of infected B cells (donor 5) and one with a low 
frequency (donor 9), were examined after 6 and 18 months 
to determine how much the frequency would change. The 
mean of the measurements for donor 5 was 39 of 106 B 
cells with a standard deviation of 20 and for donor 9 was 
5 of 108 B cells with a standard deviation of 3.5 compared 
with 12.5 of 108 B cells with a standard deviation of 16 
across the group of donors. The values for the low fre- 
quency donor were always below the whole population 
mean and the values for the high frequency donor were 
always above it. Given that we can assume an error in 
the measurements of about a factor of 2, these results 
imply that the frequencies for a given donor did not fluctu- 
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Table 2. Observed and Expected Frequencies of EBV-Carrying 
Cells for Different Populations 
Frequency of EBW Cells per 
108 B Ceils 
Donor Population Observed ~ Expected b 
7 CD23- 74 84 
CD23 + <2 101 
9 CD23 47 23 
CD23 + <1 15 
5 CD80 17 25 
CD80 + <1 526 
aObserved frequency is calculated from the frequency of EBV-carrying 
cells measured by PCR (Table 1) and the percentage of B cells esti- 
mated from FACS analysis with the pan-B cell antibody anti-CD20. 
Since the positively selected populations are attached to Dynabeads, 
they cannot be analyzed by FACS. However, CD23 and CD80 are 
highly B cell specific, so we have assumed these populations are pure 
B cells. 
b Expected is the frequency calculated for a selected population as- 
suming that all the EBV-carrying cells were in that population. It is 
calculated from the frequency of EBV + cells in the unfractionated popu- 
lation as measured by PCR (Table 1) and the percentage of cells, 
bearing the selected marker based on FACS analysis. 
ate significantly over time. This suggests that the fre- 
quency in peripheral blood may be intrinsic to a given 
individual. 
The B Cells Contain Latent Infectious Virus 
We and others have reported the detection of EBV DNA in 
association with peripheral blood cells and have assumed 
that this represents latent infectious virus. However, no 
experiments have been performed to demonstrate that the 
signals are not derived from lytically infected cells or from 
virions or viral fragments attached to the outer cell surface 
via the viral receptor CD21. To test the latter possibility, 
we have compared intact cells with nuclei prepared by 
extraction with Nonidet P-40 (NP-40). The NP-40 buffer 
disrupts the outer cell membranes and should release any 
attached virions. We observed that the frequency of EBV ÷ 
cells for one donor was 1.6 per 107 prior to NP-40 treatment 
and 2.2 per 107 after. Therefore, the viral DNA we are 
detecting is associated with the nucleus, not the plasma 
membrane, suggesting that we are detecting latently in- 
fected cells and not adsorbed virar fragments. 
Further support for the conclusion that the cells are la- 
tently infected comes from estimates of genome copy 
number. Based on in vitro studies, latently infected cells 
have a relatively low copy number (5-100) (Adams, 1979), 
whereas lytically infected cells have a high copy number 
( -105)  (Sugden et al., 1979). Lanes 3 -10  in Figure 1B 
show the signals obtained with samples of 106 BJAB 
(EBV-) cells containing an average of one Namalwa cell. 
Since a Namalwa cell only contains one or two genomes, 
the signal represents the intensity expected for a low copy 
number. The signal obtained with 104 Namalwa cells, 
which should approximate one lytically infected cell, is 
shown in lane 1 in Figure lB.  By comparison, the signals 
obtained with E- cells at the limiting dilution, in which there 
A 
B 
C 
Donor* Freq. of Outgrowth/106Cells 
E- CD23- CD23+ 
7 1 2.5 
6 10 10 
10 2.5 7.5 
11 1 1.5 
12 3 2.5 
13 1 3 
<0.5 
Figure 5. Spontaneous Outgrowth Assays on E- Cells Fractionated 
on the Basis of CD23 and CD80 Expression 
The three populations were prepared as described for the PCR experi- 
ments and placed in culture as serial 2-fold dilutions. Outgrowth was 
assessed visually after 4-6 weeks of culture. 
(A) Shows an example of a well from the CD23 CD80- population 
demonstrating spontaneous growth. Note the presence of large irregu- 
lar single blastoid cells and large clumps of cells. The single well had 
been split 1:2 twice prior to the photograph to confirm active growth. 
(B) A well that was scored as not demonstrating spontaneous out- 
growth. Note that most of the cells are small, round, opaque, and dead. 
An occasional single viable cell can still be detected. 
(C) Shows the estimated frequencies for all donors tested. 
should only be one positive cell per sample, are shown 
in lanes 11-18 of Figure lB.  The signals obtained with 
the E- cells are similar to those with the single Namalwa 
cells and markedly weaker than the signals with the 104 
Namalwa cells. Thus, the EBV-infected E- cells contain 
low genome copy numbers, consistent with a latent rather 
than a lytic infection. 
Another possibility is that the virus in these cells is defec- 
tive in some way such that it cannot be reactivated and 
released as true infectious virus. This could occur if the 
viral DNA was partially deleted or integrated or if the cell 
type was, for some reason, incompatible with reactivation. 
To test this possibility, we performed a classical spontane- 
ous outgrowth assay on whole E- cells and on E- cells 
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fractionated into CD23-CD80- and CD23+CD80 ÷ popula- 
tions. In the first experiment, we tested a donor (7) who 
had previously been tested in PCR analysis. As can be 
seen in Figure 5A, spontaneously growing cells could 
readily be detected in the E- and CD23-CD80- populations 
from this donor. The frequencies for the fractionated and 
unfractionated cells are shown in Figure 5C. No outgrowth 
was seen from the CD23÷CD80 ÷ population (e.g., Figure 
5B) at the time the experiment was terminated (9 weeks). 
Although viability of the CD23+CD80 ÷ cultures appeared 
normal over the course of the experiment, we cannot rule 
out the possibility that the positive selection process had 
an adverse effect on these cells. Nevertheless, the results 
seen by spontaneous outgrowth overall are consistent with 
the distribution of virus seen in the PCR analysis for this 
donor. To confirm that infectious virus could reproducibly 
be obtained from the CD23-CD80- population, we per- 
formed outgrowth assays on E- cells from five donors be- 
fore and after rigorous depletion of the CD23÷CD80 ÷ popu- 
lation. The results are summarized in Figure 5C. In every 
case, the CD23-CD80- population readily gave rise to 
spontaneously proliferating cell lines. Furthermore, the 
frequency of outgrowth from the CD23-CD80- population 
was always equal to or higher than for the E- population. 
Therefore, the CD23-CD80- B cell population contains in- 
fectious latent virus and is a real site of latent persistence 
by EBV. 
The PCR Products Are Derived from Donors 
and Not from Laboratory Contamination 
Since we were potentially detecting single EBV molecules 
in large excesses of DNA from PBMCs, it was important 
to perform many controls to show the specificity of our 
techniques. Beyond those already mentioned, we have 
also isolated the PCR products from three different donors 
(5, 6, and 7) and sequenced them to confirm that we were 
indeed amplifying EBV-dedved sequences. Each product 
was sequenced twice on both strands and compared with 
the sequence of the prototype laboratory strain, B95-8. 
The sequence was virtually identical to B95-8 (Baer et al,, 
1984) for all three donors as was expected, since this is 
a highly conserved region (Wagner et al., 1992). All three 
donors had two nucleotide changes. Donor 5 had a C-~T 
at position 14483, donor 6 had an A inserted at position 
14134, and donor 7 had a deletion at position 14211. In 
addition, all three donors had an additional T residue in- 
serted at position 14479, suggesting that the absence of 
this T may be a m utation characteristic of the B95-8 strain. 
For donor 7, a second PCR product, derived from a PCR 
amplification performed several months later, was also 
isolated and sequenced. The same two nucleotide 
changes were again seen (deletion at position 14211 and 
an insertion at position 14479). This proves that for this 
donor at least, the alterations een were not PCR artifacts. 
Although the number of changes seen are small, they are 
sufficient o provide evidence that our PCRs are not due 
to contamination with the laboratory strain B95-8, and, 
since the sequences varied among donors and were donor 
specific, the PCR products were not derived from aerosol 
contamination from the saliva of the investigator. 
Discussion 
Very little is known about the nature of EBV latency in vivo 
for normal asymptomatic carriers. The only model we have 
for latency in a normal cell is the in vitro immortalized EBV 
lymphoblastoid cell. In this study we set out to address 
the following question: are latently infected cells in vivo 
phenotypically l mphoblastoid? To answer this question, 
we developed a highly sensitive DNA PCR assay that de- 
tects a single EBV genome, and we used it to measure 
the frequencies of infected cells in different populations 
of PBMCs. The conclusion of this study is that the vast 
majority of latently infected cells in vivo are CD23-CD80- 
B cells and therefore are not lymphoblastoid inphenotype. 
We propose that EBV-infected B cells in vivo exhibit a 
novel phenotype and must represent a novel form of la- 
tency. 
We have performed extensive controls to assure the 
validity of the results we have obtained by PCR. Multiple 
negative control samples were included with each analysis 
and were consistently negative for all of the experiments 
described here. We have amplified a single copy cellular 
gene in samples that were EBV- to ensure that the DNA 
was a suitable template for PCR. We have tested to ensure 
that the PCR signal is due to latently infected cells, not 
copurifying virion fragments, and we sequenced several 
PCR products to confirm that donor EBV was being ampli- 
fied. Furthermore, the positive signals were enriched into 
specific populations of cells, and the frequency of positive 
samples was inversely proportional to the dilution of cells 
tested in the limiting dilution analysis. Lastly, repeat analy- 
sis of the same individuals howed reproducibility in the 
measurements. The frequency within the nine people 
tested varied by a factor of 5, whereas for a given individual 
the variation was ~<2. Having established the reliability 
of our technique, we can now apply it to resolve other 
unanswered questions about EBV latencY in vivo. 
During the course of our experiments, we obtained addi- 
tional information on the nature of the latently infected 
cells in vivo. We found that the frequency of EBV-infected 
cells in a heterogeneous collection of nine healthy adults 
was between 23 and 625 infected cells for every 10 z B 
cells. This is equivalent o about one infected B cell per 
milliliter of blood. The frequency was quite stable over the 
course of about 2 years for a given individual. We have 
also comprehensively addressed the issue of whether 
EBV is harbored in peripheral blood cell types other than 
B cells. From our observations, we can conclude that 
the B cell tropism of EBV in vitro is matched by its be- 
havior in vivo, since the virus was localized predominantly 
in the B cell compartment. It is important o stress, how- 
ever, that our observations were made on healthy adults. 
It is still conceivable that the virus may display broader 
tropism in acutely infected or immunosuppressed indi- 
viduals. 
The central issue to address now is whether or not these 
cells are proliferating. Their phenotype, CD19÷CD23 - 
CD80-, is consistent with being in a resting state. If they 
are not proliferating, then a mechanism would have to be 
invoked to replace cells that are lost over time. This loss 
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could occur if the cells enter the lytic cycle and die or 
simply experience attrition. The mechanism would have 
to involve a proliferative stage since it is not thought to 
occur through reinfection (Yao et al., 1989). For example, 
the resting cells could transiently become lymphoblastoid. 
In addition, resting cells would not need to express viral 
latent proteins and therefore would not be under immuno- 
surveillance. One prediction of this scenario is that the 
frequency of these cells will not increase in people when 
they become immunosuppressed; rather, proliferating 
CD23÷CD80 ÷ lymphoblasts, normally eliminated by CTLs, 
will now be seen in the periphery. An attractive candidate 
for persistence in a resting B cell is the long-term memory 
B cell, since immunological memory, like EBV infection, 
is for life. Memory B cells are believed to survive through 
sporadic activation by residual antigen presented by follic- 
ular dendritic cells (Tew et al., 1980). EBV could perhaps 
replace antigen in maintaining these cells. The predicted 
transient activation of resting, latently infected cells to a 
proliferative stage and the induction of the lytic cycle could 
both be regulated bythe normal physiological signals from 
the lymphoid tissue. 
However, the CD19÷CD23-CD80 --phenotype is not nec- 
essarily incompatible with proliferation. For example, ger- 
minal center centroblasts are cycling CD23- B cells (Greg- 
ory et al., 1987). If the EBV-infected cells in vivo are 
cycling, this imposes very different constraints on possible 
models of latency. The mechanism would have to involve 
some form of the stochastic model discussed in the Intro- 
duction. The cells would automatically be self-replacing, 
and expansion would have to be regulated, presumably 
by the CTL response, to limit their expansion. In this case, 
the cells would need to express latent viral genes, and it 
would be expected that their frequency would increase in 
immunosuppressed individuals. Analysis of whether or not 
the cells are proliferating and how their frequency is al- 
tered upon immunosuppression will allow us to discrimi- 
nate among these radically differenl mechanisms for EBV 
latency. 
There is precedence in tumor cells for EBV latency in 
a B cell that does not have an activated phenotype and 
is resistant to EBV-specific CTLs. This is type I Burkitt's 
lymphoma (BL). We originally suggested BL as a model 
for latently infected B cells in vivo based on the observation 
that both cell types undergo lytic replication of the virus 
when placed in culture (Thorley-Lawson, 1989). This dis- 
tinguishes them from immortalized EBV lymphoblasts, 
which are tightly latent. BL as a model for in vivo latency 
has been further developed based on the observation that 
the tumor cells only express EBNA1 (Rowe et al., 1987), 
the only latent protein not demonstrated to be a target for 
CTLs (Khanna et al., 1992). Thus, it has been suggested 
that EBNAl-only expression in the infected normal B cell 
counterpart o BL could provide a mechanism to escape 
CTL surveillance (Klein, 1994). However, there are several 
other mechanisms by which latently infected cells in vivo 
could avoid immunological surveillance. For example, 
resting cells would not need to express any latent viral 
proteins, or the virus could encode a protein that blocks 
or inhibits peptide presentation by major histocompatibility 
complex class I molecules, as has been demonstrated for 
herpes simplex virus (York et al., 1994). Furthermore, if 
the cells are proliferating, they could persist at low levels, 
despite the CTLs, through some variant of the simple sto- 
chastic model described in the introduction. Whether lim- 
ited latent gene expression in BL is representative of a 
normal B cell counterpart or whether it is an aberration of 
the tumor cell is not known. Therefore, BL remains only 
one of many possible models for in vivo latency in B cells, 
several of which have already been discussed above. Cur- 
rently, we lack the basic information needed to distinguish 
among these possibilities. 
It remains unclear what the role of EBV lymphoblasts is 
in vivo. They are present during infectious mononucleosis, 
raising the possibility that these highly proliferative cells 
are only important during the acute phase of the infection, 
providing a mechanism for rapid dissemination of the virus 
until CTLs arise to remove them. In addition, if the latent 
cells in vivo are resting, they may periodically cycle 
through a transient lymphoblastoid stage as a mechanism 
of replenishing lost cells, as discussed above. 
In conclusion, we have demonstrated that latently in- 
fected cells in vivo exhibit a form of latency distinct from 
in vitro immortalized lymphoblasts. We are now attempting 
to obtain a more detailed phenotype of these cells, which 
should allow us to describe what kind of B cells harbor 
the virus. The goal will be to assess whether these cells are 
proliferating and how they behave in immunosuppressed 
individuals and ultimately to understand EBV persistence 
in vivo and how it predisposes to neoplasia. 
Experimental Procedures 
Cell Lines 
The Namatwa (ATCC) cell line is an EBV ÷ BL that contains one or two 
integrated copies of EBV. IARC 304 (gift of Dr. G. Lenoir), ER (this 
laboratory), and IB4 (gift of Dr. E. Kieff) are immortalized EBV lymph- 
oblastoid cell lines. B JAB (gift of Dr. E. Kieff) is an EBV- B cell 
lymphoma. All of the cell lines were maintained in RPM11640 supple- 
mented with 10% fetal bovine serum (FBS). 
To determine the sensitivity of PCR, Namalwa ceils were diluted 
into B JAB cells so that there were 40 tubes with an average of two 
EBV ÷ cells per 106 B JAB cells and 20 tubes with an average of one 
EBV ÷ cell per 106 B JAB cells. This sensitivity of the PCR has been 
confirmed repeatedly throughout he course of the experiments de- 
scribed here. in addition, every frequency reported for various popula- 
tions was measured by performing a limiting dilution analysis and 
demonstrating a linear relationship between the number of cells per 
sample and the log of the fraction of samples that were negative as 
expected for detecting single events based on the Poisson distribution. 
Peripheral Blood Isolation 
Heparinized peripheral blood (180-240 ml) from healthy adult donors 
was layered onto FicoiI-Hypaque (Pharmacia). Buffy coats were re- 
moved and washed with heparin (1 U/ml) in 10/o FBS, RPM11640. T 
cells (E ÷) and non-T cells (E-) were separated as described previously 
(Hurley and Thoriey-Lawson, 1988). The T cells (E ÷) were further puri- 
fied by two rounds of depletion with magnetic beads coated with an 
antibody to the pan-B cell marker CD19 as described below. 
Magnetic Bead Separations 
E cells were resuspended in 1% FBS, RPMI 1640 at 2 x 107 cells/ 
ml. Magnetic beads (Dynal) coated with antibody against CD19 were 
washed twice according to the specifications of the manufacturer and 
added to the E- cells at a ratio of 4:1 and to the E ÷ cells at a ratio of 
7:1. Tubes were attached to a rotator (6-10 rpm) at 4°C for 30 min. 
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The bead-coated cells were removed from the uncoated cells using 
a Dynal MPC-E magnetic stand for 2-3 min. The positively selected 
cells were washed five times to remove any nonspecifically bound 
cells. Cells from each population were aliquoted into microcentrifuge 
tubes. 
For depletion of CD23 ÷ and CD80 ÷ cells, the specific antibodies 
were adsorbed onto Dynabeads M-450 coated with sheep anti-mouse 
IgG (for EBVCS#5) or uncoated beads (for anti-B7). Optimal conditions 
for binding of the beads were defined as described in the instructions 
of the manufacturer. Binding efficiency was assessed by visually ob- 
serving the number of beads that bound to ER cells, a CD23 ÷ EBV 
lymphoblastoid cell line. As a final control, the beads were tested for 
their ability selectively to deplete EBV lymphoblasts from artificial cell 
mixtures. Normal PBMCs were seeded with EBV lymphoblasts from 
the IB4 cell line at ratios of one IB4 cell to 100 or 104 PBMCs. After 
treatment with the antibody-coated beads, it was possible to demon- 
strate by FACS analysis that >195% of the IB4 cells had been removed. 
The beads were used to deplete cells from peripheral blood E- cells 
following the same procedure used for CD19, except the ratio of beads 
to cells was 10:1. Positively selected cells were not washed, but directly 
aliquoted into microcentrifuge tubes. Cell recovery was assessed at 
every step throughout the fractionation procedures to ensure that sig- 
nificant numbers of cells were not lost or dead. 
Nuclei Isolation 
E cells (10 ~) were washed with PBS (pH 7.4) and resuspended with 
100 Id of NP-40 lysis buffer (10 mM Tris [pH 7.4], 10 mM NaCI, 3 mM 
MgCI2, 0.5O/o [v/v] NP-40; Sigma). The suspensions were incubated 
on ice for 5 min, centrifuged at 500 x g for 5 min, and resuspended 
in 100 p,I of NP-40 lysis buffer. After a second centrifugation, the pellets 
were resuspended in proteinase K buffer, and DNA was extracted as 
described below. 
FACS Analysis and Antibodies 
For depletion experiments, ascite fluid was prepared from the anti- 
CD23 EBVCS#5 hybridoma line (supplied by Dr. B. Sugden). Ascite 
fluid from the anti-CD80 B7 hybridoma line was a gift from Dr. A. 
Freedman. Whole peripheral blood and subfractionated populations 
were assessed for purity by staining with antibodies to the following 
markers: CD20, pan-B cell marker (B1; gift from Dr. A. Freedman); 
CD14, monocyte marker (3C10; from ATCC); CD3, T cell marker 
(OKT3; from ATCC); CD23, B cell activation marker (EBVCS#5); CD80, 
B cell activation marker (biotinylated anti-B7; gift from Dr. G. Freeman); 
and CD19 (FITC conjugated; DAKO). As negative controls, MOPC 21 
(IgG1 isotype control; Sigma), la2 (IgG2a isotype control; this labora- 
tory), and MOPC 121 (IgG2b isotype control; Sigma) were used. Where 
necessary, either FITC-conjugated rabbit anti-mouse (Cappel) or phy- 
coerythrin-conjugated streptavidin (DAKO) was used. Propidium io- 
dide was added to all samples to distinguish live from dead cells. 
Samples were analyzed using a Becton-Dickinson FACScan with Ly- 
sys II software. 
DNA Extractions 
DNA was isolated essentially as described by Coen (1990). Pelleted 
DNA was air dried and resuspended in 50 or 25 Id of HPLC H20. 
Oligonucleotides 
Primers (22 bp) were made from the BamHI W repeat region of EBV. 
They were (forward) 5'-CTTTAGAGGCGAATGGGCGCCA-3' and (re- 
verse) 5'-TCCAGGGCCTTCACTTCGGTCT-3'. The reverse primer 
was suggested by Dr. S. Speck, and the forward primer was derived 
to be compatible in length and GC content. These primers amplified 
the region between 14068 and 14562 to give a product of 495 bp. To 
determine whether the extracted DNA was a suitable template for 
PCR, i,e,, to test for false negatives, we used primers against the 
single copy cellular gane bc/-2 (Wyatt et al., 1992). 
PCRs 
PCRs were performed in a final volume of either 50 or 100 I~1 with up 
to 4 t~g of DNA per reaction. DNA was denatured for 10 min at 95°C. 
During this time, amplification mixture containing 20 pmol of each 
primer, 200 ~tM dNTPs (Pharmacia), 50 mM KCI, 10 mM Tris (pH 8.3), 
2.0 mM MgCI2, 2.0 U of Taq polymerase (Perkin Elmer-Cetus) was 
added ("hot start"). The reactions were either amplified in a DNA Ther- 
mal Cycler 4800 or GeneAmp PCR System 9600 (Perkin Elmer-Cetus). 
For the DNA Thermal Cycler 4800, GeneAmp PCR tubes were used 
with an overlay of mineral oil. The DNA was denatured for 15 s at 
95°C, annealed at 64°C for 15 s, and extended at 72°C for 30 s for 
a total of 30 cycles with the last cycle having an extension of 72°C 
for 5 min. For the GeneAmp PCR System 9600, MicroAmp reaction 
tubes were used with no mineral oil. The protocol was essentially the 
same except the DNA was denatured at 94°C for 15 s and annealed 
and extended at 66°C for 60 s. Amplification of bcl-2 used all the same 
reagents except the primers, and the final MgCI2 concentration was 
1.5 mM These reactions were amplified in the DNA Thermal Cycler 
4800 using the same conditions as for the BamHI W repeat, except 
the annealing temperature was 55°C. For each set, there were 36 
samples, of which 8-10 were negative controls, containing DNA from 
106 B JAB cells; one was a no DNA control, and one to three were 
positive controls, usually DNA from 104 Namalwa cells. 
PCR products were fractionated on a large (24 cm x 20.5 cm) 3% 
Nusieve, 0.6% SeaKem agarose gel (FMC). The molecular weight 
marker used was ~X174 DNA digested with Hinfl (New England Bio- 
medical). Products were then transferred by capillary action onto Ny- 
tran (Schleicher & Schuell), following the protocol of the manufac- 
turer. The membranes were probed with a PCR product from the W 
repeat of either IARC 304 or Namalwa, labeled with [e-32P]dATP and 
[~-32P]dCTP (3000 Ci/mM; ICN or Dupont-New England Nuclear Re- 
search Products) by the random priming method according to the in- 
structions of the manufacturer (Boehringer-Mannheim). The mem- 
branes were hybridized and washed following the recommended 
protocol for Nytran. 
PCR products for sequencing were isolated by pooling three sam- 
ples from the same donor and fractionating on a 3% Nusieve, 0.6% 
agarose gel with 1 p.g/ml ethidium bromide. Products that were about 
500-550 bp in length were isolated onto DEAE paper (Schleicher & 
Schueil). The DNA was recovered following a modified version of the 
protocol of the manufacturer. DNA was eluted using a high salt NET 
buffer (1.0 M NaCI, 0.1 mM EDTA, 20 mM Tris [pH 8.0]). Ethidium 
bromide was removed by extracting with water-satu rated butanol. The 
aqueous phase was extracted once with equal volumes of phenol and 
chloroform:isoamyl a cohol (24:1) and twice with chloroform:isoamyl 
alcohol (24:1) alone. DNA was precipitated with 1/10 vol of 3 M sodium 
acetate (pH 6.0) and 2.5 vol of 95o/0 ethanol. Isolated DNA was washed 
with 700/0 ethanol and dissolved in TE (10 mM Tris [pH 8.0], 1 mM 
EDTA). DNA was ligated into the TA cloning plasmid pCRII (Invitrogen), 
which was specifically designed for cloning PCR products. The Iigated 
plasmid was then transformed into One Shot competent bacteria (In- 
vitrogen) that were grown on LB-agar-ampicillin plates (100 p.g/ml). 
Colonies were picked based on blue-white color selection. White colo- 
nies were grown in small cultures and miniprep DNA prepared using 
Promega Magic Miniprep kits. The plasmid DNA was digested with 
EcoRI to identify plasmids with inserts, and the inserts were sequenced 
by the dideoxy chain termination method performed with a Sequenase 
kit (U. S. Biochemicals) according to the instructions of the manufac- 
turer. Sequencing reactions were analyzed on an 8% polyacrylamide 
gel (Protogel). 
Spontaneous Outgrowth Assay 
Peripheral blood cell populations were fractionated as described 
above. The outgrowth assay was performed as described by Lam et 
al. (1991) or by Yao et al. (1991). In the later case, the tissue culture 
medium was supplemented with 50 I~M ~-thioglycerol, 20 nM bathocu- 
proinedisulfonic acid, and 1 mM sodium pyruvate to increase cloning 
efficiency (M. Falk and G. Bornkamm, personal communication). Out- 
growth was assessed visually based initially on the medium turning 
yellow and then by microscopic examination as exemplified in Figures 
5A and 5B. Continued proliferation was confirmed for donors 6 and 
7 by explanting several cultures and expanding them into lymphoblas- 
told cell lines, and the presence of EBV in the cells was confirmed by 
PCR. 
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